# TROPION-Urothelial03: what clinicians are saying

> 25 statements from 9 sources (7 posts, 1 paper, 1 registry record), 12 of them from 4 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026.

## Report

- Trial: A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03)
- NCT ID: NCT07129993
- Registry: https://clinicaltrials.gov/study/NCT07129993
- Sponsor: Daiichi Sankyo
- Phase: Phase 2/Phase 3
- Status: Recruiting
- Drugs tested: datopotamab deruxtecan
- Indication: advanced urothelial carcinoma after enfortumab vedotin plus pembrolizumab
- Version: v1.0.0, edition 1
- Accepted: 2026-11-20 UTC
- Last checked: 2026-11-20 UTC
- Release hash: a47fa664a78565558530a560d4fe9baada48d52d5c3418a9573127dc2193fdfb

## Counts

- Commentary sources screened: 12
- Sources cited by verified statements: 9
- Verified statements: 25
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 12
- Findings: 4
- Named people in screened sources (unnamed speakers and accounts not counted): 4
- Speakers cited: 4
- Cited speakers with a verified identity: 4
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 4
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 4
- By role and specialty (the abstract's specialty counts):
  - 2 physician, Medical oncology
  - 1 physician, specialty not confirmed
  - 1 physician, Urology
- Organisational or shared accounts (not counted as people): 3

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A urologist frames TROPION-Urothelial03 as addressing platinum’s limited activity, while a speaker’s relayed assessment describes platinum as still active; the estimates use different measures and are not directly comparable. The urologist cites TROP2 expression as grounds for investigation, not demonstrated benefit. Trial-specific commentary is limited; FGFR3/HER2 testing and trials for fit patients provide treatment-choice context. These accounts cannot establish comparative benefit or trial-specific tolerability.

## Question clinicians left open

What randomized evidence do clinicians need from TROPION-Urothelial03 on response and survival with datopotamab deruxtecan plus platinum versus gemcitabine plus platinum in advanced urothelial carcinoma progressing after enfortumab vedotin plus pembrolizumab, given differing accounts of platinum activity?

From finding F1 (7 statements from 2 speakers in 5 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. Platinum after EV/pembrolizumab: where clinicians split on its activity
  - 7 statements from 2 speakers in 5 sources.
  - 2 of the 2 named speakers in this finding take a side on this question; every named speaker in this finding is a confirmed clinician.
  - 2 of the report's 4 cited clinicians.
- F2. TROP2 after EV/pembrolizumab: what speakers say
  - 12 statements from 3 speakers in 5 sources.
  - 3 of the report's 4 cited clinicians.

### Beyond the trial population

- F3. Sequencing: what speakers say
  - 2 statements from 1 speaker in 2 sources.
  - 1 of the report's 4 cited clinicians.
- F4. After EV/pembrolizumab: what speakers say
  - 4 statements from 1 speaker in 3 sources.
  - 1 of the report's 4 cited clinicians.

2 of the 4 findings and 6 of the 25 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 7 | 5 | 5 | 2 | 3 |
| F2 | 12 | 8 | 5 | 3 | 3 |
| F3 | 2 | 2 | 2 | 1 | 3 |
| F4 | 4 | 3 | 3 | 1 | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 4 | 1 | 0 | 0 | 2 | 8 | 1 | 4 posts and articles, 1 publication |
| F2 | 4 | 0 | 1 | 1 | 6 | 13 | 0 | 3 posts and articles, 1 publication, 1 registry |
| F3 | 1 | 0 | 1 | 0 | 0 | 2 | 1 | 2 posts and articles |
| F4 | 2 | 1 | 0 | 0 | 1 | 4 | 1 | 3 posts and articles |

### Trial dimensions

- Primary endpoint: Overall Response Rate - Part A (Phase 2): F2 (1 shared claims)
- Primary endpoint: Progression Free Survival as Assessed by Blinded Independent Central Review (BICR) - Part B (Phase 3): F2 (1 shared claims)
- Primary endpoint: Overall Survival - Part B (Phase 3): F2 (1 shared claims)
- Secondary endpoint: Duration of Response - Part A (Phase 2): no finding draws on it directly
- Secondary endpoint: Progression Free Survival as Assessed by Investigator - Part B (Phase 3): no finding draws on it directly
- Secondary endpoint: Overall Response Rate - Part B (Phase 3): no finding draws on it directly
- Population and setting: F1 (2 shared claims), F2 (4 shared claims)
- The comparison: F1 (5 shared claims), F2 (4 shared claims)
- Safety and tolerability: no finding draws on it directly
- Design and conduct: F1 (1 shared claims), F2 (2 shared claims)

## Abbreviations

- ADC: antibody–drug conjugate
- BICR: blinded independent central review
- HCP: healthcare professional
- HER2: human epidermal growth factor receptor 2
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 6 sections | Paid |
| Verified statements with short source quotes and links | 25 | Paid |
| Who said each statement: the cited speakers | 4 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 4 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 4 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 14 | Free |
| Sources with links | 9 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 4 of the 4 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

10 discussed · 4 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Overall Response Rate - Part A (Phase 2) | discussed | 1 | 1 |
| Primary endpoint: Progression Free Survival as Assessed by Blinded Independent Central Review (BICR) - Part B (Phase 3) | discussed | 1 | 1 |
| Primary endpoint: Overall Survival - Part B (Phase 3) | discussed | 1 | 1 |
| Secondary endpoint: Duration of Response - Part A (Phase 2) | no commentary found | 0 | 0 |
| Secondary endpoint: Progression Free Survival as Assessed by Investigator - Part B (Phase 3) | no commentary found | 0 | 0 |
| Secondary endpoint: Overall Response Rate - Part B (Phase 3) | no commentary found | 0 | 0 |
| Population and setting | discussed | 7 | 5 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 8 | 5 |
| Safety and tolerability | no commentary found | 0 | 0 |
| Design and conduct | discussed | 2 | 1 |
| Post-EV/pembrolizumab unmet need and sequencing uncertainty | discussed | 6 | 6 |
| TROP2 rationale and expectations for investigation | discussed | 3 | 3 |
| Routine-care alternatives and upfront biomarker work-up | discussed | 2 | 2 |
| Fit-patient trial preference and alternative ADC regimens | discussed | 2 | 2 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Posts · 18 statements · 72%** | | | |
| X threads | 15 | 6 | 11 |
| LinkedIn posts | 3 | 1 | 1 |
| **Primary sources · 7 statements · 28%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 6 | 1 | not screened |
| Registry (primary source, cited for context) | 1 | 1 | not screened |

- Screened window: 2026-02-28 to 2026-11-13
- Cited window: 2026-02-28 to 2026-11-13
- Retrieved: 2026-11-20

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Randomized, Open-Label, Phase 2/3 Study of Datopotamab Deruxtecan (Dato-DXd) Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Who Progressed During or After Enfortumab Vedotin (EV) Plus Pembrolizumab Combination Treatment TROPION-Urothelial03 (TU03)
- Registry: NCT07129993 (https://clinicaltrials.gov/study/NCT07129993)
- Study IDs: DS1062-328
- Sponsor: Daiichi Sankyo
- Collaborators: AstraZeneca
- Design: Phase 2/Phase 3 · interventional, randomized, sequential, phase2, phase3
- Status: Recruiting
- Enrollment: 630 (estimated)
- Start: 2025-09-26 (actual)
- Primary completion: 2029-06-01 (estimated)
- Primary endpoint: Overall Response Rate - Part A (Phase 2) (From Phase 2 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 34 months)
- Primary endpoint: Progression Free Survival as Assessed by Blinded Independent Central Review (BICR) - Part B (Phase 3) (From Phase 3 randomization to the first documented radiographic disease progression or death due to any cause, whichever occurs first, up to approximately 38 months)
- Primary endpoint: Overall Survival - Part B (Phase 3) (From Phase 3 randomization to death due to any cause, up to approximately 38 months)
- Intervention: Dato-DXd (drug)
- Intervention: Carboplatin (drug)
- Intervention: Cisplatin (drug)
- Intervention: Gemcitabine (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on platinum chemotherapy, biomarker-directed therapies, emerging antibody-drug conjugates and clinical trials after EV plus pembrolizumab.
- 13 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 43 sources about other trials or topics are not included.
- The available discussion is concentrated in public posts and short summaries. Full talks and reviews are not represented, so the reasoning behind some estimates and preferences cannot be fully assessed.
- Reposts and quoted posts do not establish additional independent HCP views or agreement.
- Platinum estimates differ in endpoint, wording and evidence source. They should not be combined into a single expected response or survival estimate for the trial's comparator.
- The review's lack of a signal favoring cisplatin over carboplatin is not evidence of equivalence.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The TROPION-Urothelial03 material used here describes methods and prospective expectations. Supporting observations from other Dato-DXd studies concern different regimens and, for TROPION-Lung04, a different cancer.
- Post dates are not presentation or session dates and do not establish changes in a clinician's opinion.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-20 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-20 UTC. No changes.

## Offer

- Size: Focused · 25 verified statements · 12 from 4 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (4 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/tropion-urothelial03-nct07129993
- Agents: POST https://www.erudio.com/api/orders with {"report": "tropion-urothelial03-nct07129993", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=tropion-urothelial03-nct07129993

## Cite

Erudio Health. TROPION-Urothelial03 (NCT07129993): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 20, 2026. https://www.erudio.com/reports/tropion-urothelial03-nct07129993

## Questions

### How much does the TROPION-Urothelial03 report cost?

One edition costs $750 (Focused · 25 verified statements · 12 from 4 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the TROPION-Urothelial03 report cover?

25 statements from 9 sources (7 posts, 1 paper, 1 registry record), 12 of them from 4 confirmed clinicians, each linked to its source. Commentary checked Nov 20, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the TROPION-Urothelial03 report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "tropion-urothelial03-nct07129993" }) previews it and create_order({ "report": "tropion-urothelial03-nct07129993", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the TROPION-Urothelial03 report?

Edition 1 (version 1.0.0), accepted Nov 20, 2026 UTC; last checked for new commentary Nov 20, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/tropion-urothelial03-nct07129993.json
- Markdown: https://www.erudio.com/reports/tropion-urothelial03-nct07129993.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/tropion-urothelial03-nct07129993/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "tropion-urothelial03-nct07129993"}`
